How to Read a Peptide Certificate of Analysis (CoA) | Veyvora

A peptide certificate of analysis (CoA) is a batch-specific analytical report that documents identity, purity, content and selected quality attributes of a research peptide, compared against pre-defined specifications, to support batch release and traceability rather than to prove suitability for human use [1].

By the end of this guide you will know how to verify that a CoA belongs to the physical batch in hand, what each analytical field actually proves, and where the document’s evidential limits lie.

How to read a peptide CoA, the core steps:

1. Confirm the batch or lot number on the CoA matches the pen label exactly; a genuine certificate for a different lot does not verify the material in hand.
2. Check product identity fields: peptide name, sequence, molecular formula and theoretical molecular weight.
3. Review High-Performance Liquid Chromatography (HPLC) purity as an area-percentage value, and request the chromatogram to verify peak integration.
4. Examine the mass spectrometry result (observed mass versus theoretical mass) to confirm molecular identity.
5. Read the net peptide content figure, which accounts for residual water and counter-ion mass excluded from the HPLC purity calculation.
6. Verify manufacture and retest dates to confirm the batch sits within its tested stability window.
7. Check that the issuing laboratory is named, the analytical methods are identified, and a qualified signatory has authorised the compliance conclusion.
8. Treat endotoxin, bioburden and sterility results as separately reported attributes; their absence from a CoA does not mean the tests passed.

Each field answers a different analytical question. HPLC purity measures the proportion of chromatographic signal attributed to the target peptide; it does not establish concentration, sterility or complete contaminant clearance. Veyvora states that each catalogue batch is checked independently by a third-party laboratory (Asterion Analytics) and again by Veyvora’s own internal testing, using HPLC, mass spectrometry and endotoxin testing, before sale [1].

Key Takeaways

• A CoA is batch-specific: lot numbers must match the pen label exactly before any result is meaningful.
• HPLC purity, net peptide content, mass spectrometry and microbiological attributes are four distinct parameters, none substitutes for another.
• A CoA confirms analytical conformity for the parameters tested; it does not establish human safety, sterility, biological activity or GMP compliance.
• Absent results (e.g. no endotoxin figure) indicate the result was not reported, not that the test passed.
• Post-dispatch storage conditions fall outside the CoA’s scope; consult storage and stability guidance for research peptides separately.

Reading the fields of a peptide CoA in sequence is the most reliable way to confirm that a batch meets its stated specification, because each field answers a distinct analytical question [1].

Minimum fields to verify on any peptide CoA:

1. Product identity, peptide name, sequence, molecular formula and theoretical molecular weight, confirming what was synthesised.
2. Batch or lot number, a unique identifier that must match every pen label and accompanying batch document exactly.
3. Manufacture and retest dates, the window within which the analytical results are considered valid; consult storage and stability guidance for research peptides if the retest date is approaching.
4. Physical description, appearance (for a pre-filled solution pen, typically a clear, colourless solution) as a basic conformance check on receipt.
5. HPLC purity, reported as an area-percentage value; request the raw chromatogram to verify peak integration and confirm no co-eluting impurities are obscured.
6. Mass spectrometry result, observed mass versus theoretical mass, confirming molecular identity independently of chromatographic retention.
7. Net peptide content, the proportion of the weighed material that is active peptide, after accounting for residual water and counter-ion mass; this figure differs from HPLC purity and must not be conflated with it.
8. Microbiological attributes, endotoxin and bioburden results, where tested; their absence from a CoA does not indicate the tests passed.
9. Issuing laboratory identity, name, address and, where applicable, accreditation number.
10. Analytical methods and version numbers, identifies which validated procedure generated each result.
11. Authorised signatory and compliance conclusion, a named, qualified individual’s sign-off confirming the batch meets or does not meet specification.

Unfamiliar terms such as assay, retest date or endotoxin are defined in the research peptide glossary without interrupting the CoA review workflow.

A peptide CoA documents analytical conformity for the parameters tested; it does not establish that a batch is safe for human administration, sterile, biologically efficacious or manufactured under conditions that meet regulatory requirements.

A CoA cannot establish any of the following:

• Human safety or suitability for administration. Analytical conformity with a specification is not a clinical safety assessment. Research peptides sold for laboratory use carry no authorisation for human use, and a CoA provides no basis for one.
• Sterility. Endotoxin testing, where reported, does not demonstrate freedom from viable micro-organisms, viral contamination or non-endotoxin pyrogens.
• Biological activity or in vivo stability. HPLC purity and mass spectrometry confirm chromatographic and structural properties; neither predicts receptor binding, immunogenicity or pharmacokinetic behaviour in a biological system.
• Freedom from untested impurities. A CoA reports only the parameters listed; unknown or untested impurities fall outside its scope by definition.
• Post-dispatch integrity. The CoA reflects batch status at the time of testing and cannot confirm that storage or transit conditions have preserved that status; storage and stability guidance for research peptides addresses that question separately.
• Good Manufacturing Practice (GMP) compliance or ethical sourcing. Analytical results do not verify the manufacturing facility, production process or supply-chain provenance [1].

The broader consensus across pharmacopoeial and WHO laboratory guidance is that analytical documentation must be complemented by supplier qualification, manufacturing records and, where applicable, regulatory authorisation before any broader quality conclusion can be drawn [1].

A peptide CoA sits within a broader quality framework; understanding the individual tests it reports requires separate, method-specific references.

• To understand what HPLC purity does and does not prove, including why area-percent values cannot confirm concentration, identity or sterility, consult the HPLC purity method explainer before interpreting purity figures from any batch document.
• To apply the batch-matching checks described above to a specific vial or shipment, use the step-by-step verify a CoA against your batch tool, which walks through lot-number cross-referencing, date validation and discrepancy reporting.

Eurachem’s analytical quality guides and European Pharmacopoeia general chapters, including 2.2.55 on peptide mapping and 2.6.14 on bacterial endotoxins, define the procedural standards that underpin the results reported on any compliant CoA [1].

To begin batch verification for a Veyvora research peptide, locate the lot number on your vial and retrieve the corresponding CoA from Veyvora’s research-peptide catalogue.